Regentis Biomaterials (RGNT) CMO holds options for 67,961 shares

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. Chief Medical Officer Galit Reske reported initial holdings of an employee stock option to buy 67,961 shares of common stock. The option has a $4.00 exercise price and expires on February 23, 2037.

The option was granted on February 23, 2026 and vests over three years. One-sixth of the option vests six months after the grant date, and one-twelfth vests on the last day of each subsequent three-month period, subject to continued employment.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reske Galit

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 67,961 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Underlying shares: 67,961 shares Exercise price: $4.00 per share Expiration date: February 23, 2037 +2 more

5 metrics

Underlying shares 67,961 shares Employee stock option underlying common stock

Exercise price $4.00 per share Option exercise price for common stock

Expiration date February 23, 2037 Option expiration

Grant date February 23, 2026 Option grant to Chief Medical Officer

Vesting period 3 years One-sixth at six months, then quarterly one-twelfth

Key Terms

Employee Stock Option (Right to Buy), exercise price, vesting, underlying security

4 terms

Employee Stock Option (Right to Buy) financial

"Security title is listed as Employee Stock Option (Right to Buy)."

exercise price financial

"The option has an exercise price of $4.0000 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options shall vest on a quarterly basis under the vesting schedule."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"The underlying security title is identified as Common Stock."

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reske Galit

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	02/23/2037	Common Stock	67,961	$4	D

Explanation of Responses:

1. This option was granted on February 23, 2026. The options shall vest on a quarterly basis, with one-sixth (1/6) of the options vesting upon the six-month anniversary of the grant date and one-twelfth (1/12) vesting on the last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date.

	/s/ Galit Reske	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing by RGNT’s Chief Medical Officer report?

The Form 3 filing reports initial ownership of an employee stock option. It gives Galit Reske the right to buy 67,961 shares of REGENTIS BIOMATERIALS common stock at a $4.00 exercise price, expiring on February 23, 2037.

How many RGNT shares are covered by Galit Reske’s stock option?

The option covers 67,961 underlying shares of REGENTIS BIOMATERIALS common stock. These shares are not owned outright yet; they can be purchased in the future by exercising the option at the fixed $4.00 exercise price, subject to vesting conditions.

What is the exercise price and expiration date of the RGNT stock option?

The employee stock option has a fixed $4.00 exercise price per share and expires on February 23, 2037. This means Galit Reske can buy the vested shares at $4.00 any time before that expiration date, assuming the option has vested.

When was the RGNT stock option granted to the Chief Medical Officer?

The employee stock option was granted on February 23, 2026. This grant date starts the vesting schedule, including the six-month cliff before the first portion vests and the subsequent quarterly vesting periods described in the filing’s footnote.

How does the vesting schedule work for the RGNT employee stock option?

The option vests over three years. One-sixth vests on the six-month anniversary of the February 23, 2026 grant date, and one-twelfth vests on the last day of each following three-month period, contingent on continuous employment through each vesting date.

Is Galit Reske’s ownership of the RGNT stock option direct or indirect?

The filing shows direct ownership of the employee stock option. The derivative summary identifies the ownership type as direct, meaning the option is held personally, not through a trust, LLC, or other indirect entity structure.